The doctor-initiated clinical trials are led by Prof. Kenichiro KOI and are based on the constitutive expression of a survivin gene in cancer tissue, and an adenovirus-based vector.

https://jmog.jp/治験概要説明資料_JMOG%20HP用.pdf